ANDA 79112, held by Pharmazone. Fexofenadine Hydrochloride.
As of Nov 22, 2026, ANDA 79112 (Children's Fexofenadine Hydrochloride Hives, Children's Fexofenadine Hydrochloride Allergy, Fexofenadine Hydrochloride Hives), held by Pharmazone, was first approved by FDA on Feb 8, 2012, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 8, 2012 | Original application | Approved | None posted |
| Children's Fexofenadine Hydrochloride Hives30MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Children's Fexofenadine Hydrochloride Allergy30MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Hives60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy60MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Hives180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Fexofenadine Hydrochloride Allergy180MG · tablet;oral | Fexofenadine Hydrochloride | OTC |
| Nov 14, 2014 | Supplement 1Manufacturing | Approved | None posted |
| Feb 8, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters